CHAPTER 1. METHODOLOGY AND SCOPE
1.1. MARKET SEGMENTATION & SCOPE
1.2. MARKET DEFINITIONS
1.2.1. PRODUCT
1.2.2. END USE
1.3. REGIONAL SCOPE
1.4. ESTIMATES AND FORECAST TIMELINE
1.5. RESEARCH METHODOLOGY
1.6. INFORMATION PROCUREMENT
1.6.1. PURCHASED DATABASE
1.6.2. GVR’S INTERNAL DATABASE
1.6.3. PRIMARY RESEARCH
1.7. INFORMATION OR DATA ANALYSIS
1.7.1. DATA ANALYSIS MODELS
1.8. MARKET FORMULATION & VALIDATION
1.9. MARKET MODEL
1.9.1. COMMODITY FLOW ANALYSIS
1.10. LIST OF SECONDARY SOURCES
1.11. LIST OF ABBREVIATIONS
1.12. OBJECTIVES
CHAPTER 2. EXECUTIVE SUMMARY
2.1. MARKET OUTLOOK
2.2. SEGMENT SNAPSHOT
2.3. COMPETITIVE LANDSCAPE SNAPSHOT
CHAPTER 3. MARKET VARIABLES, TRENDS, & SCOPE
3.1. MARKET LINEAGE OUTLOOK
3.1.1. PARENT MARKET OUTLOOK
3.1.2. RELATED/ANCILLARY MARKET OUTLOOK
3.2. MARKET DYNAMICS
3.2.1. MARKET DRIVER ANALYSIS
3.2.1.1. RISING DEMAND FOR CELL THERAPIES
3.2.1.2. ADVANCEMENTS IN RESEARCH AND DEVELOPMENT FOR CELL-BASED THERAPIES
3.2.1.3. TECHNOLOGICAL INNOVATION
3.2.2. MARKET RESTRAINT ANALYSIS
3.2.2.1. HIGH COST ASSOCIATED WITH THE PRODUCTION AND PROCUREMENT OF RAW MATERIALS
3.2.2.2. STRINGENT REGULATIONS ASSOCIATED WITH CELL THERAPIES
3.3. INDUSTRY ANALYSIS TOOLS
3.3.1. PORTER’S FIVE FORCES ANALYSIS
3.3.2. PESTEL ANALYSIS
3.3.3. COVID-19 IMPACT ANALYSIS
CHAPTER 4. PRODUCT BUSINESS ANALYSIS
4.1. PRODUCT SEGMENT DASHBOARD
4.2. CELL THERAPY RAW MATERIALS MARKET: PRODUCT MOVEMENT ANALYSIS
4.3. CELL THERAPY RAW MATERIALS MARKET SIZE & TREND ANALYSIS, BY PRODUCT, 2025 TO 2033
4.4. MEDIA
4.4.1. MEDIA MARKET, 2025 TO 2033
4.5. SERA
4.5.1. SERA MARKET, 2025 TO 2033
4.6. CELL CULTURE SUPPLEMENTS
4.6.1. CELL CULTURE SUPPLEMENTS MARKET, 2025 TO 2033
4.7. ANTIBODIES
4.7.1. ANTIBODIES MARKET, 2025 TO 2033
4.8. REAGENTS & BUFFERS
4.8.1. REAGENTS & BUFFERS MARKET, 2025 TO 2033
4.9. OTHERS
4.9.1. OTHERS MARKET, 2025 TO 2033
CHAPTER 5. END USE BUSINESS ANALYSIS
5.1. CELL THERAPY RAW MATERIALS MARKET: END USE MOVEMENT ANALYSIS
5.2. BIOPHARMACEUTICAL & PHARMACEUTICAL COMPANIES
5.2.1. BIOPHARMACEUTICAL & PHARMACEUTICAL COMPANIES MARKET, 2025 TO 2033
5.3. CROS & CMOS
5.3.1. CROS & CMOS MARKET, 2025 TO 2033
5.4. OTHERS
5.4.1. OTHERS MARKET, 2025 TO 2033
CHAPTER 6. REGIONAL BUSINESS ANALYSIS
6.1. CELL THERAPY RAW MATERIALS MARKET SHARE BY REGION
6.2. NORTH AMERICA
6.2.1. NORTH AMERICA CELL THERAPY RAW MATERIALS MARKET, 2025 TO 2033
6.2.2. U.S.
6.2.2.1. KEY COUNTRY DYNAMICS
6.2.2.2. COMPETITIVE SCENARIO
6.2.2.3. REGULATORY FRAMEWORK
6.2.2.4. U.S. CELL THERAPY RAW MATERIALS MARKET, 2025 TO 2033
6.2.3. CANADA
6.2.3.1. KEY COUNTRY DYNAMICS
6.2.3.2. COMPETITIVE SCENARIO
6.2.3.3. REGULATORY FRAMEWORK
6.2.3.4. CANADA CELL THERAPY RAW MATERIALS MARKET, 2025 TO 2033
6.2.4. MEXICO
6.2.4.1. KEY COUNTRY DYNAMICS
6.2.4.2. COMPETITIVE SCENARIO
6.2.4.3. REGULATORY FRAMEWORK
6.2.4.4. MEXICO CELL THERAPY RAW MATERIALS MARKET, 2025 TO 2033
6.3. EUROPE
6.3.1. EUROPE CELL THERAPY RAW MATERIALS MARKET, 2025 TO 2033
6.3.2. UK
6.3.2.1. KEY COUNTRY DYNAMICS
6.3.2.2. COMPETITIVE SCENARIO
6.3.2.3. REGULATORY FRAMEWORK
6.3.2.4. UK CELL THERAPY RAW MATERIALS MARKET, 2025 TO 2033
6.3.3. GERMANY
6.3.3.1. KEY COUNTRY DYNAMICS
6.3.3.2. COMPETITIVE SCENARIO
6.3.3.3. REGULATORY FRAMEWORK
6.3.3.4. GERMANY CELL THERAPY RAW MATERIALS MARKET, 2025 TO 2033
6.3.4. FRANCE
6.3.4.1. KEY COUNTRY DYNAMICS
6.3.4.2. COMPETITIVE SCENARIO
6.3.4.3. REGULATORY FRAMEWORK
6.3.4.4. FRANCE CELL THERAPY RAW MATERIALS MARKET, 2025 TO 2033
6.3.5. ITALY
6.3.5.1. KEY COUNTRY DYNAMICS
6.3.5.2. COMPETITIVE SCENARIO
6.3.5.3. REGULATORY FRAMEWORK
6.3.5.4. ITALY CELL THERAPY RAW MATERIALS MARKET, 2025 TO 2033
6.3.6. SPAIN
6.3.6.1. KEY COUNTRY DYNAMICS
6.3.6.2. COMPETITIVE SCENARIO
6.3.6.3. REGULATORY FRAMEWORK
6.3.6.4. SPAIN CELL THERAPY RAW MATERIALS MARKET, 2025 TO 2033
6.3.7. DENMARK
6.3.7.1. KEY COUNTRY DYNAMICS
6.3.7.2. COMPETITIVE SCENARIO
6.3.7.3. REGULATORY FRAMEWORK
6.3.7.4. DENMARK CELL THERAPY RAW MATERIALS MARKET, 2025 TO 2033
6.3.8. SWEDEN
6.3.8.1. KEY COUNTRY DYNAMICS
6.3.8.2. COMPETITIVE SCENARIO
6.3.8.3. REGULATORY FRAMEWORK
6.3.8.4. SWEDEN CELL THERAPY RAW MATERIALS MARKET, 2025 TO 2033
6.3.9. NORWAY
6.3.9.1. KEY COUNTRY DYNAMICS
6.3.9.2. COMPETITIVE SCENARIO
6.3.9.3. REGULATORY FRAMEWORK
6.3.9.4. NORWAY CELL THERAPY RAW MATERIALS MARKET, 2025 TO 2033
6.4. ASIA PACIFIC
6.4.1. ASIA PACIFIC CELL THERAPY RAW MATERIALS MARKET, 2025 TO 2033
6.4.2. JAPAN
6.4.2.1. KEY COUNTRY DYNAMICS
6.4.2.2. COMPETITIVE SCENARIO
6.4.2.3. REGULATORY FRAMEWORK
6.4.2.4. JAPAN CELL THERAPY RAW MATERIALS MARKET, 2025 TO 2033
6.4.3. CHINA
6.4.3.1. KEY COUNTRY DYNAMICS
6.4.3.2. COMPETITIVE SCENARIO
6.4.3.3. REGULATORY FRAMEWORK
6.4.3.4. CHINA CELL THERAPY RAW MATERIALS MARKET, 2025 TO 2033
6.4.4. INDIA
6.4.4.1. KEY COUNTRY DYNAMICS
6.4.4.2. COMPETITIVE SCENARIO
6.4.4.3. REGULATORY FRAMEWORK
6.4.4.4. INDIA CELL THERAPY RAW MATERIALS MARKET, 2025 TO 2033
6.4.5. AUSTRALIA
6.4.5.1. KEY COUNTRY DYNAMICS
6.4.5.2. COMPETITIVE SCENARIO
6.4.5.3. REGULATORY FRAMEWORK
6.4.5.4. AUSTRALIA CELL THERAPY RAW MATERIALS MARKET, 2025 TO 2033
6.4.6. THAILAND
6.4.6.1. KEY COUNTRY DYNAMICS
6.4.6.2. COMPETITIVE SCENARIO
6.4.6.3. REGULATORY FRAMEWORK
6.4.6.4. THAILAND CELL THERAPY RAW MATERIALS MARKET, 2025 TO 2033
6.4.7. SOUTH KOREA
6.4.7.1. KEY COUNTRY DYNAMICS
6.4.7.2. COMPETITIVE SCENARIO
6.4.7.3. REGULATORY FRAMEWORK
6.4.7.4. SOUTH KOREA CELL THERAPY RAW MATERIALS MARKET, 2025 TO 2033
6.5. LATIN AMERICA
6.5.1. LATIN AMERICA CELL THERAPY RAW MATERIALS MARKET, 2025 TO 2033
6.5.2. BRAZIL
6.5.2.1. KEY COUNTRY DYNAMICS
6.5.2.2. COMPETITIVE SCENARIO
6.5.2.3. REGULATORY FRAMEWORK
6.5.2.4. BRAZIL CELL THERAPY RAW MATERIALS MARKET, 2025 TO 2033
6.5.3. ARGENTINA
6.5.3.1. KEY COUNTRY DYNAMICS
6.5.3.2. COMPETITIVE SCENARIO
6.5.3.3. REGULATORY FRAMEWORK
6.5.3.4. ARGENTINA CELL THERAPY RAW MATERIALS MARKET, 2025 TO 2033
6.6. MEA
6.6.1. MEA CELL THERAPY RAW MATERIALS MARKET, 2025 TO 2033
6.6.2. SOUTH AFRICA
6.6.2.1. KEY COUNTRY DYNAMICS
6.6.2.2. COMPETITIVE SCENARIO
6.6.2.3. REGULATORY FRAMEWORK
6.6.2.4. SOUTH AFRICA CELL THERAPY RAW MATERIALS MARKET, 2025 TO 2033
6.6.3. SAUDI ARABIA
6.6.3.1. KEY COUNTRY DYNAMICS
6.6.3.2. COMPETITIVE SCENARIO
6.6.3.3. REGULATORY FRAMEWORK
6.6.3.4. SAUDI ARABIA CELL THERAPY RAW MATERIALS MARKET, 2025 TO 2033
6.6.4. UAE
6.6.4.1. KEY COUNTRY DYNAMICS
6.6.4.2. COMPETITIVE SCENARIO
6.6.4.3. REGULATORY FRAMEWORK
6.6.4.4. UAE CELL THERAPY RAW MATERIALS MARKET, 2025 TO 2033
6.6.5. KUWAIT
6.6.5.1. KEY COUNTRY DYNAMICS
6.6.5.2. COMPETITIVE SCENARIO
6.6.5.3. REGULATORY FRAMEWORK
6.6.5.4. KUWAIT CELL THERAPY RAW MATERIALS MARKET, 2025 TO 2033
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1. COMPANY CATEGORIZATION
7.2. STRATEGY MAPPING
7.3. COMPANY POSITION ANALYSIS, 2024
7.4. COMPANY PROFILES
7.4.1. THERMO FISHER SCIENTIFIC INC.
7.4.1.1. OVERVIEW
7.4.1.2. FINANCIAL PERFORMANCE
7.4.1.3. PRODUCT BENCHMARKING
7.4.1.4. STRATEGIC INITIATIVES
7.4.2. MERCK KGAA
7.4.2.1. OVERVIEW
7.4.2.2. FINANCIAL PERFORMANCE
7.4.2.3. PRODUCT BENCHMARKING
7.4.2.4. STRATEGIC INITIATIVES
7.4.3. DANAHER
7.4.3.1. OVERVIEW
7.4.3.2. PRODUCT BENCHMARKING
7.4.3.3. STRATEGIC INITIATIVES
7.4.4. SARTORIUS STEDIM BIOTECH
7.4.4.1. OVERVIEW
7.4.4.2. PRODUCT BENCHMARKING
7.4.4.3. STRATEGIC INITIATIVES
7.4.5. ACTYLIS
7.4.5.1. OVERVIEW
7.4.5.2. PRODUCT BENCHMARKING
7.4.5.3. STRATEGIC INITIATIVES
7.4.6. ACROBIOSYSTEMS
7.4.6.1. OVERVIEW
7.4.6.2. FINANCIAL PERFORMANCE
7.4.6.3. PRODUCT BENCHMARKING
7.4.6.4. STRATEGIC INITIATIVES
7.4.7. STEMCELL TECHNOLOGIES.
7.4.7.1. OVERVIEW
7.4.7.2. FINANCIAL PERFORMANCE
7.4.7.3. PRODUCT BENCHMARKING
7.4.7.4. STRATEGIC INITIATIVES
7.4.8. GRIFOLS, S.A.
7.4.8.1. OVERVIEW
7.4.8.2. PRODUCT BENCHMARKING
7.4.8.3. STRATEGIC INITIATIVES
7.4.9. CHARLES RIVER LABORATORIES
7.4.9.1. OVERVIEW
7.4.9.2. PRODUCT BENCHMARKING
7.4.9.3. STRATEGIC INITIATIVES
7.4.10. ROOSTERBIO, INC.
7.4.10.1. OVERVIEW
7.4.10.2. FINANCIAL PERFORMANCE
7.4.10.3. PRODUCT BENCHMARKING
7.4.10.4. STRATEGIC INITIATIVES
7.4.11. PROMOCELL GMBH
7.4.11.1. OVERVIEW
7.4.11.2. FINANCIAL PERFORMANCE
7.4.11.3. PRODUCT BENCHMARKING
7.4.11.4. STRATEGIC INITIATIVES
著作権 ©2022 無断複写・転載を禁じます
